JP2022539585A5 - - Google Patents
Info
- Publication number
- JP2022539585A5 JP2022539585A5 JP2022500080A JP2022500080A JP2022539585A5 JP 2022539585 A5 JP2022539585 A5 JP 2022539585A5 JP 2022500080 A JP2022500080 A JP 2022500080A JP 2022500080 A JP2022500080 A JP 2022500080A JP 2022539585 A5 JP2022539585 A5 JP 2022539585A5
- Authority
- JP
- Japan
- Prior art keywords
- polypeptide
- antigen
- cells
- cell
- nucleic acid
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP19184742 | 2019-07-05 | ||
| EP19184742.5 | 2019-07-05 | ||
| PCT/GB2020/051594 WO2021005339A1 (en) | 2019-07-05 | 2020-07-03 | Novel cancer antigens and methods |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2022539585A JP2022539585A (ja) | 2022-09-12 |
| JP2022539585A5 true JP2022539585A5 (enExample) | 2023-07-13 |
| JP7834016B2 JP7834016B2 (ja) | 2026-03-23 |
Family
ID=67211535
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022500080A Active JP7834016B2 (ja) | 2019-07-05 | 2020-07-03 | 新規な癌抗原及び方法 |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US20220211760A1 (enExample) |
| EP (1) | EP3994156A1 (enExample) |
| JP (1) | JP7834016B2 (enExample) |
| KR (1) | KR20220034039A (enExample) |
| CN (2) | CN120005001A (enExample) |
| AU (1) | AU2020312230A1 (enExample) |
| BR (1) | BR112022000133A2 (enExample) |
| CA (1) | CA3141990A1 (enExample) |
| IL (1) | IL289334A (enExample) |
| MX (1) | MX2022000262A (enExample) |
| WO (1) | WO2021005339A1 (enExample) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BR112021006941A2 (pt) | 2018-10-19 | 2021-08-31 | The Francis Crick Institute Limited | Antígenos de câncer inovadores e métodos |
| TW202241925A (zh) | 2021-01-15 | 2022-11-01 | 德商英麥提克生物技術股份有限公司 | 用於不同類型癌症免疫治療的ｈｌａ展示肽 |
| US20250054576A1 (en) | 2021-12-17 | 2025-02-13 | Evaxion Biotech A/S | Personalized cancer therapy targeting normally non-expressed sequences |
| WO2025202937A1 (en) | 2024-03-26 | 2025-10-02 | BioNTech SE | Cancer vaccines |
Family Cites Families (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0871747A1 (en) | 1996-01-02 | 1998-10-21 | Chiron Viagene, Inc. | Immunostimulation mediated by gene-modified dendritic cells |
| US6770456B1 (en) | 1998-07-29 | 2004-08-03 | Ludwig Institute For Cancer Research | Endogenous retrovirus tumor associated nucleic acids and antigens |
| AU2001249922A1 (en) * | 2000-04-06 | 2001-10-23 | Pharmacia And Upjohn Company | G protein-coupled receptors |
| US7193069B2 (en) * | 2002-03-22 | 2007-03-20 | Research Association For Biotechnology | Full-length cDNA |
| EP1586330A1 (en) | 2004-04-16 | 2005-10-19 | Georg-August-Universität Göttingen | Vaccination against malignant melanoma |
| DK1871391T3 (da) | 2005-03-30 | 2012-04-16 | Viroxis | Endogen retrovirus og proteiner, der kodes af env som target for cancerbehandling |
| AT502292B1 (de) | 2005-05-11 | 2010-04-15 | Avir Green Hills Biotechnology | Melanomdiagnose |
| US8921050B2 (en) | 2006-03-17 | 2014-12-30 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Methods of diagnosing renal cell carcinoma |
| US20080019979A1 (en) | 2006-05-22 | 2008-01-24 | Feng Wang-Johanning | HERV-K Antigens, Antibodies, and Methods |
| EP2052088A2 (en) * | 2006-08-02 | 2009-04-29 | Genizon Biosciences | Genemap of the human genes associated with psoriasis |
| WO2009026116A2 (en) * | 2007-08-16 | 2009-02-26 | Genizon Biosciences, Inc. | Genemap of the human genes associated with longevity |
| GB201521746D0 (en) * | 2015-12-10 | 2016-01-27 | Immatics Biotechnologies Gmbh | Novel peptides and combination of peptides for use in immunotherapy against CLL and other cancers |
| GB201521894D0 (en) * | 2015-12-11 | 2016-01-27 | Immatics Biotechnologies Gmbh | Novel peptides and combination of peptides for use in immunotherapy against various cancers |
| CR20180551A (es) * | 2016-04-21 | 2019-02-12 | Immatics Biotechnologies Gmbh | Inmunoterapia contra el melanoma y otros tipos de cáncer |
| US10384736B2 (en) * | 2016-07-13 | 2019-08-20 | Marcelo A. Pizarro | Dual oscillating cycle saddle and support system |
-
2020
- 2020-07-03 EP EP20737270.7A patent/EP3994156A1/en active Pending
- 2020-07-03 CN CN202411890938.5A patent/CN120005001A/zh active Pending
- 2020-07-03 CN CN202080049064.4A patent/CN114174323B/zh active Active
- 2020-07-03 JP JP2022500080A patent/JP7834016B2/ja active Active
- 2020-07-03 WO PCT/GB2020/051594 patent/WO2021005339A1/en not_active Ceased
- 2020-07-03 MX MX2022000262A patent/MX2022000262A/es unknown
- 2020-07-03 KR KR1020217040818A patent/KR20220034039A/ko not_active Ceased
- 2020-07-03 CA CA3141990A patent/CA3141990A1/en active Pending
- 2020-07-03 BR BR112022000133A patent/BR112022000133A2/pt not_active IP Right Cessation
- 2020-07-03 AU AU2020312230A patent/AU2020312230A1/en not_active Abandoned
-
2021
- 2021-12-17 US US17/644,931 patent/US20220211760A1/en active Pending
- 2021-12-23 IL IL289334A patent/IL289334A/en unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2022539585A5 (enExample) | ||
| Senovilla et al. | Trial watch: DNA vaccines for cancer therapy | |
| Han et al. | Ferritin protein cage nanoparticles as versatile antigen delivery nanoplatforms for dendritic cell (DC)-based vaccine development | |
| Chesson et al. | Antigenic peptide nanofibers elicit adjuvant-free CD8+ T cell responses | |
| JP2022540396A5 (enExample) | ||
| JP2022538609A5 (enExample) | ||
| JP2022514116A5 (enExample) | ||
| CN102947452A (zh) | 使用用于癌症的辅佐治疗的李斯特菌属的方法和组合物 | |
| CA2994272C (en) | Modified yeast-brachyury immunotherapeutic compositions | |
| CN106243213B (zh) | 一种肿瘤相关抗原XAGE-1b短肽及应用 | |
| JP2022539157A5 (enExample) | ||
| CN118076378A (zh) | 包含肿瘤相关抗原衍生肽以及由脂肽和免疫活性物质组成的佐剂的抗癌疫苗组合物及其用途 | |
| US20230054958A1 (en) | Ctl peptide epitopes and antigen-specific t cells, methods for their discovery, and uses thereof | |
| CN109970846A (zh) | 一种肿瘤相关抗原XAGE-1b九肽及其应用 | |
| Mesa et al. | Very small size proteoliposomes derived from Neisseria meningitidis: an effective adjuvant for generation of CTL responses to peptide and protein antigens | |
| JP2014139185A5 (enExample) | ||
| JP2011506497A5 (enExample) | ||
| CN106279392B (zh) | 肿瘤相关抗原XAGE-1b短肽及其应用 | |
| JP2018528960A5 (enExample) | ||
| Zhu et al. | Tumor antigen delivered by Salmonella III secretion protein fused with heat shock protein 70 induces protection and eradication against murine melanoma | |
| Brinkhoff et al. | Microsphere priming facilitates induction of potent therapeutic T‐cell immune responses against autochthonous liver cancers | |
| JP2022501046A (ja) | アルギナーゼ１ポリペプチド | |
| CN104341530A (zh) | Vnsak多肽及其应用 | |
| Huang et al. | Reprogramming the genome of M13 bacteriophage for all-in-one personalized cancer vaccine | |
| He et al. | Induction of MUC1-specific cellular immunity by a recombinant BCG expressing human MUC1 and secreting IL2 |